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ABSTRACT
Mammary gland tumours are the most common neoplasia diagnosed in the female dog. 
These tumours occur spontaneously or naturally as in humans, 50% of which are commonly 
diagnosed as malignant. Metastasis to other tissues especially the lung is a common cause of 
death in these dogs. Treatment of canine mammary gland tumours (CMT) involves mainly 
surgical resection with wide margin followed by chemotherapy with cytotoxic drugs for 
those with lymph node and distant metastasis. With the dog continuously described as a 
very suitable and valuable large animal model of human breast cancer, it becomes very 
obvious that CMT can be a model to further understand the biology of cancer as well 
as screening for new therapeutic agents that could be used to treat human breast cancer 
and CMT more effectively. This review focuses on research work that has been done on 
CMT over the past years, describing the epidemiology, diagnostics and recent advances 
in therapy for CMT as well as discussing the significance of the dog CMT as spontaneous 
animal model for human breast cancer.
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INTRODUCTION
In mammals, a modification of sweat 
gland results in the formation of the 
mammary gland, consisting of a network 
of ducts that are surrounded by adipose-
rich fibrovascular stroma (Santos, Marcos, 
& Faustino, 2010; Sorenmo, Rasotto, 
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Zappulli, & Goldschmidt, 2011). In the 
canine species there are seven to 16 
duct openings on each teat that extend 
to form a lobe (independent functional 
unit) of the canine mammary gland. In 
most dogs, five pairs of mammary glands 
develop, but in some, it can occasionally 
range from four or six pairs (Sorenmo et 
al., 2011). The five pairs of glands include 
a cranial thoracic, caudal thoracic, cranial 
abdominal, caudal abdominal, and inguinal 
(Figure 1). 
Figure 1. Anatomic positions of the five canine mammary glands
Canine Mammary Gland Tumour
A mammary tumour is an abnormal growth 
of tissue originating in the mammary 
gland. The tumour could be benign or 
malignant involving teats and glands 
that extend from the cranial thoracic to 
the inguinal of both sides of the midline. 
Mammary gland tumours are the most 
common neoplasia diagnosed in the 
female dog, accounting for up to 50% of 
all neoplasms diagnosed (Egenvall et al., 
2005; Kelsey, Moore, & Glickman, 1998; 
Sahabi, Selvarajah, Noordin, Sharma, & 
Dhaliwal, 2015; Zuccari, Castro, Gelaleti, 
& Mancini, 2011). Like other tumours, 
canine mammary gland tumours occur 
spontaneously or naturally as in humans 
(Andrade, Figueiroa, Bersano, Bissacot, 
& Rocha, 2010). Fifty percent of CMT 
are diagnosed as malignant according to 
reports from other geographical locations 
(Benjamin, Lee & Saunders, 1999; Dhami, 
Tank, Karle, Vedpathak, & Bhatia, 2010; 
Klopfleisch, Lenze, Hummel, & Gruber, 
2011a). Metastasis to other tissues 
especially the lungs and lymphatics are 
common causes of death in the affected 
dogs (Rasotto, Zappulli, Castagnaro, & 
Goldschmidt, 2012). 
Prevalence
The prevalence of canine mammary gland 
tumours (CMT) reported varies between 
dog populations. A high prevalence of more 
than 70% have been reported (Benjamin et 
al., 1999) in Colorado, United States of 
America (USA), in a life-span observation 
study involving 672 female beagles that 
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were experimentally exposed to radiation. 
An incidence of 51% per year for CMT in 
clinical cases in the USA has been reported 
Kelsey et al. (1998). In Sweden, a study 
was conducted involving a population of 
more than 80,000 insured female dogs 
and the incidence of CMT was reported 
to be 111 dogs per 10,000 dog year at 
risk (DYAR) (Egenvall et al., 2005). In 
clinical reports on CMT, the incidence 
reported from Europe ranges from 26.5% 
to 70% (Merlo et al., 2008; Valenčáková-
Agyagosová & Ledecký, 2011). An 
incidence of 205 cases/100,000 dogs/year 
in the United Kingdom was also reported 
by Dobson, Samuel,  Milstein, Rogers, & 
Wood (2002). In India, the prevalence of 
CMT was reported to be 24.3% to 39.9% 
(Dhami et al., 2010;  Srivastava, Sharma, 
& Singh, 2009). In Malaysia, Sahabi et 
al., 2015 reported a prevalence of 39% for 
CMT among all neoplasia cases diagnosed 
in the pathology laboratory of the Faculty 
of Veterinary Medicine, Universiti Putra 
Malaysia, from 2006 to 2012. In a survey 
of tumours of domestic animals in South 
Africa, over a 40-year period, CMT was 
grouped under genital tract tumours in 
female dogs. The genital tract tumours 
make up 10.2% of the tumours affecting 
dogs and the CMT subgroup make up 80% 
of the genital tract tumours (Bastianello, 
1983). At the time of diagnosis, a range 
between 52% to 86% of the mammary 
gland tumours in the dog have been 
reported as malignant (Klopfleisch, Lenze, 
Hummel, & Gruber, 2011b; Zuccari et al., 
2008).  
Aetiopathogenesis and Risk Factors
Hormonal Influence. As a bitch grows, 
mammary stem cell differentiation into 
ductal, alveolar and myoepithelial cells 
is regulated by hormones. Oestrogen is 
involved in the proliferation of the duct while 
progesterone is involved in the development 
of alveoli in the mammary gland of animals 
(Toniti, Buranasinsup, Kongcharoen, 
Puchadapirom, & Kasorndorkbua, 2009). 
At maturity, the release of oestrogen initiates 
mammary gland development, which is 
completed during and after pregnancy by 
progesterone and prolactin respectively 
(Sorenmo et al., 2011). The activity of 
progesterone peaks during pregnancy 
and the diestrous phase of the oestrous 
cycle in the intact bitch, resulting in the 
development of lobules and ducts lined by 
multiple layers of epithelium. Prolonged 
diestrous (prolonged progesterone activity) 
and exposure to progestegens (progesterone 
based contraceptives) have been shown to 
induce CMT development (Gräf & Etreby, 
1978). The activity of oestrogen receptors 
is a major stimulator of cell proliferation 
in mammary epithelium, and has a close 
physiological association with progesterone 
receptor expression (Klopfleisch et al., 
2011c). One of the most important causes 
of mammary gland tumour development in 
dogs is early exposure to ovarian hormones 
(Sorenmo et al., 2011). Endocrine aetiology 
of canine mammary tumour is well-defined, 
with non-spayed (intact) bitches having 
four times higher risk than bitches spayed 
before two years of age (Queiroga, Raposo, 
Carvalho, Prada, & Pires (2011).
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Immunohistochemical studies have 
identified oestrogen and progesterone 
receptors in benign and malignant tumours, 
which strongly points to a hormonal 
cause (Queiroga et al., 2011). Variable 
proportions of oestrogen receptors (ER) in 
malignant and benign tumours have been 
demonstrated by immunohistochemical 
and biomedical methods and its presence 
has been associated with a favourable 
prognosis (Martin De Las Mulas et al., 
2004). Two isoforms of the oestrogen 
receptors are known - oestrogen receptor 
alpha (ERα) and oestrogen receptor beta 
(ERβ), with the former being the major 
oestrogen receptor (Balfe et al., 2004). 
Canine mammary tumour progression from 
benign to malignant is related to steroid 
dependency, as receptors of oestrogen and 
progesterone were expressed in 70% benign 
and 50% malignant tumours (Philibert et al., 
2003). Using immunohistochemistry, it was 
revealed that ERβ-positive tumours were 
largely more benign than malignant (Martin 
De Las Mulas et al., 2004). Generally ER 
positive CMT and more differentiated 
compared to ER negative CMT (MacEwen, 
Patnaik, Harvey, & Panko, 1982)    
Age. Age is said to be one of the very 
important factors that influence the 
risk of canine mammary gland tumour 
development. Research carried out in a 
large closed beagle colony showed that 
mammary neoplasia occurs mainly in 
adult dogs (Taylor et al., 1976). According 
to the same study, the incidence rate of 
CMT remained low in dogs up to seven 
years of age (the earliest cancer occurred 
at seven years of age). At eight years of 
age, a sharp rise in the incidence was 
observed, which remained high as the age 
increases. In a study by Sahabi et al., 2015, 
the mean age of occurrence of CMT in the 
dog population was 8.66 years, while the 
median age was nine years. Moreover, age 
of the dogs was significantly associated 
with CMT development in the dogs. No 
mammary tumour was seen in a population 
of over 500 male dogs in the said study. The 
earliest age for mammary gland tumour in 
dogs however, may vary between breeds 
according to the natural life span. A range 
of eight to 11 years is reported as the age 
of dogs affected by CMT (Sorenmo et 
al., 2011). A progressive increase in the 
incidence of mammary gland tumour was 
observed in dogs from three to nine years 
of age, after which the frequency declined 
and reached its lowest at 15 years (Mitchell, 
De la Iglesia, Wenkoff, Van Dreumel, & 
Lumb, 1974).               
Breed Predisposition. Mammary gland 
tumour is more common in toy and 
miniature breeds (Itoh, et al., 2005; Mitchell 
et al., 1974; Philibert et al., 2003; Sorenmo 
et al., 2011; Zatloukal, Lorenzova, & Tichý, 
2005). According to a study carried out in 
Sweden by Egenvall et al. (2005) involving 
more than 80,000 insured female dogs, the 
incidence of CMT varied between breeds. 
The English springer spaniel had incidence 
of 319 dogs per 10,000 DYAR, while the 
Rough Collie had an incidence of five dogs 
in 10,000 DYAR. Poodle was the shown to 
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be the most susceptible breed representing 
25% of 720 dogs with mammary gland 
tumour cases (Mitchell et al., 1974). Larger 
breeds such as Afghan Hound, Brittany 
Spaniel, English Setter, German Shepherd 
and Pointer are also at an increased risk 
of mammary gland tumour development 
(Sorenmo et al., 2011). Pure breed dogs are 
reported to have a higher representation 
in CMT compared to mixed breed (Perez 
Alenza, Peña, Del Castillo, & Nieto, 2000; 
Philibert et al., 2003; Sahabi et al., 2015; 
Zatloukal et al., 2005) .
Obesity. Mammary gland tumour 
development in dogs has been linked to 
obesity. Dogs that are  obese at one year 
of age or if they are obese at one year 
before the diagnosis of CMT, have a higher 
prevalence of mammary gland tumour than 
those that do not (Perez Alenza et al., 2000; 
Philibert et al., 2003). A decreased risk of 
developing mammary gland tumour in dogs 
is associated with poor body condition at 
nine to 12 months of age, but interestingly 
enough, obese animals of the same age 
in the study did not have a higher risk of 
mammary gland tumour development 
(Sorenmo et al., 2011). In another study, 
there was little or no association between 
adult body conformations with the risk 
of CMT in intact or spayed bitches 
(Sonnenschein, Glickman, Goldschmidt, & 
McKee, 1991). Obesity increases the 
risk of breast cancer development in 
postmenopausal women, due to increasing 
local and free circulating oestrogen. Obesity 
in dogs may influence the development 
of mammary gland tumour via the same 
mechanisms (Sorenmo et al., 2011). A 
high intake of beef, pork and a decreased 
consumption of chicken has been linked 
to a high incidence of mammary gland 
tumour in dogs (Perez Alenza et al., 2000). 
The development and biological behaviour 
of mammary gland tumour are believed 
to be influenced by body fat content, as 
Philibert et al. (2003) reported a shorter 
survival of obese dogs with mammary 
gland tumour, compared to those with poor 
body condition at nine to 12 months of age.
Clinical Presentation
Typically, the owner of the dog will present 
their pet dogs to the veterinarian with a 
primary complaint of lump(s) observed 
on the mammary gland(s) (Figure 2). 
Depending on the tumour type, and /
or time taken from the start of tumour 
development to the time of presentation to 
the veterinarian, other clinical signs such 
as ulceration around the affected gland(s), 
anorexia, pyrexia, emaciation, change in 
gait, signs of pain, in some cases, anaemia 
and other signs of systemic illnesses can 
occur. The caudal abdominal and inguinal 
mammary glands are most commonly 
affected as compared to other glands in 
the dog (Sahabi et al., 2015; Sorenmo et 
al., 2011). This has been suggested to be 
attributable to a more abundant glandular 
tissue and the larger size and the longer 
time of secretory activity in the abdominal 
and inguinal glands (Mitchell et al., 1974). 
Furthermore, low incidence of mammary 
gland tumour in male dogs could be due 
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to the absence of the influence of ovarian 
hormones (oestrogen and progesterone) on 
the mammary tissue, and a smaller amount 
of susceptible tissue, which are both 
characteristics in female dogs (Taylor et 
al., 1976). A dog could have more than one 
tumour in its mammary gland(s), freely 
movable or fixed, presented with ulcerative 
surface, small or large (Mitchell et al., 
1974; Sorenmo et al., 2011). 
Figure 2. Dogs with spontaneously developed natural mammary gland tumours
Metastasis
Metastasis is when a cell from a primary 
tumour leaves the tumour, gets into 
systemic circulation, and invades a distant 
site to establish a secondary tumour 
(Woodhouse, Chuaqui, & Liotta, 1997). 
Metastasis through the haematogenous 
route to the lungs has been found to be 
a common cause of deaths in dogs with 
malignant CMT (Klopfleisch et al., 2011a; 
Rasotto et al., 2012). Another route of 
metastasis is via the lymphatic system to 
the draining lymph node, from where it will 
invade other tissues of the body (Rasotto et 
al., 2012). For these reasons, staging of the 
disease in a human breast cancer patient 
or a dog mainly involves examination of 
the lungs and regional lymph nodes for 
abnormalities and to seek possible evidence 
of metastasis to other body systems from 
the examination (Table 1).
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Table 1
Sites for metastasis in dogs with mammary gland tumours
Organ/tissue of metastasis References
Lymph node(s) (Kim et al., 2011; Sorenmo et al., 2000)
Lung (Sorenmo et al., 2011)
Liver, kidney and spleen (Kim et al., 2011; Valenčáková-Agyagosová & Ledecký, 2011) 
Brain, eye, skin, bone, heart (Kim et al., 2011; Valenčáková-Agyagosová & Ledecký, 2011) 
Diagnostic Investigations
In any condition, diagnosis starts with 
history taking and obtaining signalment of 
the dog including information on age, breed, 
neuter status, breeding information, use of 
exogenous hormones, history of trauma 
and vaccinations. Physical examination 
should include examinations that do not 
focus on the affected mammary glands but 
also other systems in the body to detect 
presence of concurrent illnesses. During 
examination of the tumour, the following 
should be noted: size, site, number of 
affected glands and the surrounding 
tissues, whether they are sessile, movable 
or ulcerated. The regional lymph node(s) 
should be carefully palpated and examined 
to evaluate enlargements, which could be 
possible in cases of metastasis. 
Differential diagnoses typical for 
masses such as hematoma, abscessation, 
cyst formation, granuloma or neoplasia / 
hyperplasia have to be included for masses 
involving the mammary glands. However, 
it is difficult to diagnose neoplasia just by 
observation of the masses, especially those 
with only a single gland affected. Canine 
mammary tumours can appear cystic, 
presented with infection and necrotic 
tissue (pus) or even ulceration with active 
bleeding. Infections on the mammary 
tumour are relatively common because of 
the high possibility for the dog to lick or 
bite on the tumour; or contaminated with 
soil bacteria when the dog lies down. 
Diagnostic Cytology. Fine needle 
aspiration (FNA) and diagnostic cytology 
has been described as a valuable 
diagnostic tool (Santos et al., 2013) 
(Figure 3). Although easy to perform, 
tumour classification is difficult, as tissue 
architecture is not available in FNA 
(Hellmén & Lindgren, 1989). Fine needle 
aspiration is very important in the initial 
stage of the diagnosis as it helps to exclude 
differential diagnoses such as mastitis, 
abscessation and hyperplasia (Cassali et 
al., 2011), with an accuracy rate of 79% 
reported (Hellmén & Lindgren, 1989). 
When there is ulceration or discharge 
present from the affected teat, an impression 
smear of the ulcerated site or discharge can 
be useful specimen to facilitate diagnostic 
cytology. In such cases, there is no need to 
perform an active FNA or incisional biopsy 
sampling. 
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Figure 3. Impression smear cytology of an ulcerated tumour 
The figure shows an ulcerated 
tumour of a mammary gland in a dog 
for cytology showing marked cell size 
variation (anisocytosis), irregular nuclear-
cytoplasmic ratio, bare nuclei (black arrow) 
and irregular nuclear size -anisokaryosis 
(white arrows). The two images above are 
magnified 400 times while the two below 
are magnified x1000.    
Diagnostic Imaging. There are many 
different diagnostic imaging modalities 
available in veterinary practice including 
radiography, magnetic resonance imaging 
(MRI) and computed tomography (CT). 
Radiography is widely available even in 
small local veterinary practices, which 
can be incorporated to help determine 
the prognosis of disease. However, this 
imaging method is not sensitive to evaluate 
metastasis to lymph nodes or other soft 
tissues. For the dog with mammary 
gland tumour, thoracic radiography is 
most essential for evaluation of possible 
pulmonary metastasis. Ideally, three thoracic 
radiographic views are recommended 
for this purpose - the ventro-dorsal, right 
lateral and left lateral views (Cassali et 
al., 2011). Diagnostic ultrasonography 
can be performed to evaluate the internal 
soft tissue organs for possible metastasis 
and even combined with FNA guided by 
ultrasonographic techniques to evaluate 
metastasis using cytology. Abdominal 
ultrasonography is used when metastasis to 
other anatomical sites is suspected during 
physical examination, or if haematological 
abnormalities are noted (Cassali et al., 2011; 
Matos, Baptista, Gärtner, & Rutteman, 
2012; Novosad, 2003). Other advanced 
imaging modalities such as MRI and CT 
have been used to detect micrometastasis 
in clinical cases but their usefulness for 
the general practitioners and in staging of 
the affected dogs are limited. Computed 
tomography (CT) is a sensitive technique 
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that is able to detect micro-metastasis to 
the lungs of less than six mm in diameter 
(Cassali et al., 2011; Matos et al., 2012). 
Computed tomography may also be used to 
monitor response to therapy (Matos et al., 
2012). 
Histopathology. Histopathology is the 
method of choice and has been described 
as the “gold standard” to achieve an 
accurate diagnosis for CMT (Cassali et al., 
2011; Rasotto et al., 2012). It allows for the 
study of the histopathology characteristics 
of the tumour such as the mitotic index, 
differentiation, degree of pleomorphism, 
amount of necrosis, and invasion of 
neoplastic cells into adjacent blood vessels 
and lymphatic and the evaluation of margins 
of the excised tumour (Cassali et al., 2011). 
Routine histopathology is performed using 
hematoxylin and eosin staining protocols, 
which most of the time are sufficient 
for diagnosing CMT. However, selected 
subtypes or histopathology variants of CMT 
could be more difficult to diagnose using 
routine staining and require special staining 
or immunohistochemistry techniques for 
an accurate diagnosis (Matos et al., 2012).
World Health Organization (WHO), 
in 1974, presented the first international 
histological classification of tumours 
of domestic animals and in 1999, a 
modification (Table 2) of the classification 
system was published (Hampe & Misdorp, 
1974; Misdorp, Else, & Hellmen, 1999). 
These were the basis for the classification 
of tumours in domestic animals including 
mammary gland tumours of the dog. 
Recently, some modifications to the 
classification systems for canine mammary 
tumours were proposed because of the need 
to incorporate newly described histologic 
subtypes of CMT (Goldschmidt, Peña, 
Rasotto, & Zappulli, 2011).
Table 2
The World Health Organization (WHO) classification (1999) of canine mammary gland tumours
Tumour type Tumour sub-type
1. Malignant tumours 1.1 Non-infiltrating (in situ) carcinoma
1.2 Complex carcinoma
1.3 Simple carcinoma
      1.3.1 Tubulopapillary carcinoma
      1.3.2 Solid carcinoma
      1.3.3 Anaplastic carcinoma
1.4 Special types of carcinomas
      1.4.1 Spindle cell carcinoma
      1.4.2 Squamous cell carcinoma
      1.4.3 Mucinous carcinoma
      1.4.4 Lipid rich carcinoma
1.5 Sarcoma
      1.5.1 Fibrosarcoma
      1.5.2 Osteosarcoma
      1.5.3 Other sarcomas
1.6 Carcinosarcoma
1.7 Carcinoma or sarcoma in benign tumour
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Table 2 (continue)
Tumour type Tumour sub-type
2. Benign tumours 2.1 Adenoma
      2.1.1 Simple adenoma
      2.1.2 Complex adenoma
      2.1.3 Basaloid adenoma
2.2 Fibroadenoma
      2.2.1 Low-cellularity fibroadenoma
      2.2.2 High-cellularity fibroadenoma
2.3 Benign mixed tumour
2.4 Duct papilloma 
3. Unclassified tumours
4. Mammary hyperplasia and   
    dysplasia 4.1 Ductal hyperplasia4.2 Lobular hyperplasia
      4.2.1 Epithelial hyperplasia
      4.2.2 Adenosis
4.3 Cysts
4.4 Duct ectasia
4.5 Focal fibrosis (fibrosclerosis)
4.6 Gynecomastia
A brief description of the 
histopathology features of the types of 
canine mammary gland tumours (Cassali 
et al., 2011; Goldschmidt et al., 2011) is 
described below.  
Benign Mammary Gland Tumours
Adenoma. This type of tumour is 
composed of well differentiated epithelial 
or myoepithelial cells. It is classified as 
simple tubular type. The solid nodes are 
composed of fusocellular cells and are 
called myoepitheliomas. It is a rare tumour 
in dogs.
Complex Adenomas or 
Adenomyoepitheliomas. The origin of this 
tumour is from continuous proliferation of 
myoepithelial and epithelial cells, without 
forming myxoid matrix. It is characterised 
by having a capsule, no necrosis, atypia 
and low mitosis.
Basaloid Adenoma. This type of tumour 
consists of uniform cords on basaloid 
monomorphic epithelial cells nest. The cells 
of the periphery are arranged side-by-side 
manner and are oriented against a thin basal 
lamina. In most cases the tumours are small.
Fibroadenoma. This type of tumour 
originates from the proliferation of 
stromal and epithelial elements. Two sub 
types are described as: (1) pericanicular 
fibroadenoma (the stroma surrounds 
the epithelium) and (2) intracanicular 
fibroadenoma (the stroma compresses and 
deforms the epithelium).   
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Benign Mixed Tumour. This type of 
tumour consists of proliferated cells 
that appear either fusiform or stellate, 
morphologically resembling mesenchymal 
cells and epithelial components, producing 
adipose tissue and/or cartilage and/or bone, 
sometimes with fibrous tissue. The cells 
are sometimes embedded in abundant 
myxoid matrix. There is some level of 
pleomorphism and atypia. It is the most 
common benign tumour in dogs.
Ductal Papilloma. This type of tumour is 
lobed or ramified in a distended duct. There 
is proliferation of the epithelium of ducts 
on a fibro-vascular axis. Cellular atypia 
is evident on the epithelium, and nuclear 
hyperchromasia. There is minimal mitotic 
activity and the epithelium is distributed as a 
single layer on a layer of myoepithelial cells.
Malignant Mammary Gland Tumours
Ductal Carcinoma In-situ. This is the most 
common of the two types of carcinoma in-situ, 
the other type is lobular ductal carcinoma in-
situ. It is often associated with invasive canine 
mammary carcinomas. The tumour develops 
in the extra- or intra-lobular ducts. DCIS is 
characterised by the proliferation of epithelial 
cells in more than two ductal units in one 
histological section. The cellular architecture 
of the cells is atypical, characterised by 
connecting bridges in the ductal lumen. 
There is also polarisation of epithelial cells 
in a layer associated with another continuous 
layer comprising myoepithelial cells. There 
are micro-calcifications seen in the ductal 
lumen.
Lobular Carcinoma In-situ. In this type 
of tumour, epithelial proliferation causes 
the filling and expansion of the terminal 
lobular units.  About 50% of the lobe is 
affected and the lumen is completely lost, 
but the basement membrane is maintained. 
The cells have the same shape, with small 
and spherical nuclei. The nuclei are small 
with discrete and uniform nucleoli. There is 
noticeable invagination of the cytoplasmic 
membrane due to a single vacuole around 
the nucleus.  
Carcinoma in a Mixed Tumour. Mixed 
tumours exhibit a complex histological 
pattern, having cellular components from 
epithelial and mesenchymal origin. Some 
of the cells can turn malignant, giving rise 
to carcinoma in mixed tumours. Carcinoma 
in mixed tumours composed of nodules or 
foci of highly pleomorphic epithelial cells 
with atypical mitoses, arising in benign 
mixed tumours. 
Complex Carcinoma or Malignant 
Adenomyoepitheliomas. This tumour is 
made up of epithelial and myoepithelial 
cells proliferation. However, myxoid 
matrix is not evident. Other features 
include atypia, necrosis, and absence of a 
capsule and high mitotic activity.
Papillary Carcinoma. Papillary 
aborescent epithelial proliferation with a 
central fibrovascular stroma characterises 
this tumour. These lesions are classified as 
papilloma, carcinoma in-situ in papilloma, 
papillary carcinoma in-situ, invasive and 
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non-invasive papillary carcinomas. In 
benign tumours, neoplastic papillae that 
have within them myoepithelial cells could 
be observed between basement membrane 
and the epithelial cells. This characteristic 
is not seen in the malignant variant. 
Tubular Carcinoma. Predominantly 
tubular arrangement of the proliferated 
epithelial cells qualifies this type of tumour. 
The amount of stroma is variable. With or 
without necrosis, peritumoural lymphocytes 
can be seen. The rate of tissue and vessel 
invasion is high in these tumours.  
Solid Carcinoma. This is a common 
cancer of dogs that is usually seen when the 
tumour has stayed for a long time without 
surgical intervention. On histopathology, 
the epithelial cells are solidly arranged in 
chords, sheets or clusters. The cells are not 
differentiated, with small hyperchromatic 
nuclei with a high mitotic index. In some 
cases, the cells will exhibit vacuolated 
cytoplasm. There is variable amount (small 
to moderate) of stroma and areas of necrosis. 
Micropapillary Carcinoma. Microscopically, 
this tumour is characterised by the 
presence of cystic spaces that look like 
lymphatic vessels distributed within the 
mammary gland tissue. Within the spaces, 
a micropapillary pattern which is morule 
like, is assumed by clusters of epithelial 
cells. The cytoplasm is eosinophilic and 
abundant. The nucleus is vesicular and 
pleomorphic with prominent nucleoli. 
Lymph node metastasis is common and the 
mitotic index is variable. For confirmation, 
immunohistochemistry can demonstrate 
the epithelial membrane antigen which will 
be the form of micropapillary arrangement 
of the cells.
Invasive Lobular Carcinoma. This type 
of CMT shows small cells in a linear 
arrangement, which are non-polar and are 
uniform in size. The tumour is diffusely 
invasive with large amount of fibrous 
stroma. Solid foci may be formed by the 
tumour cells, containing mucin and having 
a signet appearance, or arranged around 
benign ducts in a parallel way.
Pleomorphic Lobular Carcinoma. First 
found in dogs in 2002, this tumour is a 
result of the dispersal of epithelial cells in 
the stroma, or an irregular outline of the 
cells in a linear pattern. The cytoplasm is 
abundant and eosinophilic with accentric 
and pleomorphic nuclei. Cytoplasmic 
vacuoles are sometimes seen.
Secretory Carcinoma. With fine needle 
aspiration biopsy (FNAB), the cells are 
round to oval and in the form of clusters. 
The nucleoli are fragmented and the 
chromatin is irregularly distributed. The 
cells have a clear and abundant cytoplasm 
with the nucleus pushed to the periphery by 
secretory vacuoles. Histopathologically, this 
tumour is seen as an infiltrative carcinoma, 
with the neoplastic cells having peripherally 
displaced nucleus by large vacuoles 
and a clear cytoplasm. The proliferation 
pattern could be solid and/or tubular with 
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eosinophilic spaces filled with secretion. In 
secretory carcinoma, the intracytoplasmic 
content of the cells is PAS positive. 
Mucinous Carcinoma. The presence of 
abundant extracellular mucinous material 
characterises this tumour. It is also known 
as gelatinous carcinoma. The proliferated 
cells may form solid, tubular or papillary 
structure. Large amount of mucinous 
eosinophilic secretions fill the spaces in 
these structures. The secretion is also PAS 
positive in diastase and alcian blue. The 
accumulated mucin is mostly located in 
the intraductal structure. When the mucoid 
content leaks from the intraductal structure, 
it then becomes invasive mucinous 
carcinoma.
Lipid-rich Carcinoma. This tumour is 
uncommon in dogs and is characterised by 
an expansive growth. The stroma separates 
the nests and cords of neoplastic cells. The 
cytoplasm of the cells is vacuolated and 
the nuclei are round to flat. There may be 
peripheral displacement of the nucleus by 
vacuoles. When 80% of the tumour cells are 
lipid producing, the diagnosis is confirmed. 
The cells of this tumour are PAS negative.
Squamous Cell Carcinoma.  This tumour 
is characterised by areas of squamous 
differentiation in the solidly arranged sheets 
and cords of tumour cells. Keratin pearls 
(keratin layers) are found in the centre of 
the more differentiated tumour. Invasion 
of the lymphatics in these tumours is not 
uncommon.
Spindle Cell Carcinoma. This tumour 
is not very common in dogs. On 
histopathology, there is presence of spindle 
cells in bundles or in a circular pattern. The 
cytoplasm of the cells appears eosinophilic 
and might be vacuolated. The nuclei could 
also be vacuolated with a fragmented 
chromatin. These features should be seen 
in at least 80% of the tumour section in 
order to confirm the diagnosis.
Anaplastic Carcinoma. This histologic 
sub type of CMT is highly aggressive 
with early metastasis and recurrence and 
is considered to have the worst prognosis. 
This tumour is diffusely infiltrative. The 
proliferating epithelial cells are large, 
atypical with linear outline. The stroma 
is loose, abundant and reactive, with 
individual cells invading it. The cells are 
also anaplastic, with one or two prominent 
nucleoli and chromatin fragmentation. 
The tumour has a high mitotic index 
with marked anisocytosis. Blood and 
lymphatic vascular structures invasion by 
neoplastic cells could be observed and one 
of the prominent features of this tumour is 
inflammation.
Fibrosarcoma. These tumours are 
malignant and are made up of fibroblasts 
with varying amounts of collagen. 
Collagen-producing spindle-shaped cells 
are arranged as reticular fibres form these 
tumours. Fibrosarcomas are among the 
most encountered mammary sarcomas in 
the dog. 
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Osteosarcoma. This sarcoma is 
characterised by the formation of bone 
and/or osteoid by the neoplastic cells. 
Osteosarcoma could occur as combined 
or non-combined (pure). The combined 
form has both osseous and cartilaginous 
malignant tissues. There is high mitoses 
and pleomorphism. 
Carcinosarcoma. In the dog, the features 
of carcinosarcoma resemble those 
described in humans. The cut surfaces of 
these tumours are firm to bony with a clear 
delineation. The cells are epithelial-like and 
well delineated. The type of differentiation 
varies including solid, adeno, mucinous, 
anaplastic, squamous, and sarcomatous 
areas with fibroblastic, chondroblastic and 
osteomatous differentiation. When present, 
metastasis is of mixed type, sarcomatous or 
carcinomatous.
Other Sarcomas. Other sarcomas that 
could occur in the mammary gland include 
pure chondrosarcoma, haemangiosarcoma 
and liposarcoma. These are extremely rare 
and have similar features to those observed 
in other organs. 
Blood and Urine Profile. Haematological 
abnormalities are often observed in dogs 
bearing mammary gland tumour. In human 
mammary carcinoma, thrombocytopenia 
might be used as prognostic indicator. 
In a study on 246 dogs with CMT, 
thrombocytosis, hypergammaglobulinaemia 
and neutropaenia were most obvious 
abnormalities (Lallo, Ferrarias, 
Stravino, Rodriguez, & Zucare, 2016). 
Thrombocytosis has been linked 
with systemic inflammatory reaction 
which involves interleukin-1 beta and 
interleukin-6 which is abundant in 
mammary gland tumour (Lallo et al., 
2016). Hypergammaglobulinaemia is 
due to acute or chronic inflammatory 
reaction going on at the mammary gland 
(Lallo et al., 2016). Some haematological 
changes can be due to paraneoplastic 
syndromes. Paraneoplastic syndromes are 
tumour related alterations in anatomical 
structure or function or both that take 
place further from the tumour (Bergman, 
2012). Mammary gland carcinoma or 
adenocarcinoma can cause hypercalcaemia 
(Bergman, 2012). Hypercalcaemia is due 
to pathological bone resorption caused 
by the cytokines that induce oesteoclast 
differentiation and activity. Parathyroid 
hormone-related protein (PTHrP) is one 
of the cytokine involved in oesteoclast 
differentiation and activity. PTHrP is also 
secreted by normal mammary gland during 
lactation. Thus, in the case of mammary 
gland tumour the production of PTHrP 
will be high which leads to hypercalcaemia 
(DeMauro & Wysolmerski, 2005). 
Urinalysis has no significant impact 
and is not able to provide prognostic 
value for dogs with CMT. However, 
there has been a study discussing the 
possibility of proteinuria development 
in dogs with mammary carcinoma 
(Crivellenti et al., 2016) which is caused 
by by-products from neoplastic cell’s 
interaction with immune cells to form 
Pertanika J. Trop. Agric. Sci. 41 (2): 541 – 574 (2018)
Review on Mammary Gland Tumours in the Dog
555
complexes and trigger release of acute 
phase proteins which can cause glomerular 
damage (Crivellenti et al., 2016). 
Figure 4 below shows some of the 
histopathology variants of CMT described 
in the literature.
Figure 4. Some of the histologic subtypes of CMT 
A is tubulopapillary carcinoma, B is solid 
carcinoma, C is squamous cell carcinoma, 
D is  ductal carcinoma, E is anaplastic 
carcinoma and  F is carcinosarcoma. 
Staging of CMT
Canine mammary gland tumours are 
staged according to the TNM system, 
namely, the tumour size, lymph node and 
metastasis (Matos et al., 2012; Sorenmo et 
al., 2011). Information about tumour size, 
lymph node involvement and presence 
of metastasis are needed to stage a CMT 
patient. The tumour with the largest 
diameter should be used for staging a CMT 
patient with more than one tumour. Fine 
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needle aspiration and subsequent cytology 
examination of the nearby draining lymph 
node should be performed if the lymph 
node is enlarged and palpable (Sorenmo 
et al., 2011). Thoracic radiography with 
at least three views should be performed 
to identify metastasis since lungs are the 
most common site of metastasis. However, 
abdominal radiography or ultrasonography 
can be performed if metastasis is suspected 
in the said anatomical location. Table 3 
summarises the original WHO staging 
system (Owen, 1980) and the modified 
WHO staging system (Rutteman & 
Withrow, 2001; Sorenmo et al., 2011). 
Staging of CMT will facilitate record 
keeping and communication between 
clinicians on the patient’s status. 
Furthermore, staging systems allow 
for comparison between patients with 
similar tumour burden, which is crucial 
when evaluating the effectiveness of 
new treatments (Sorenmo et al., 2011). 
Besides, staging of CMT correlates with 
the prognosis of the disease: an advanced 
stage confers a worse prognosis and a poor 
prognosis typically requires an escalation 
in therapy (Yamagami, Kobayashi, 
Takahashi, & Sugiyama, 1996). Thus, 
complete staging provides crucial 
prognostic information, which is 
subsequently implemented in the patient’s 
treatment plan (Goldschmidt et al., 2011; 
Sorenmo et al., 2011).
In stage I CMT of small, non-invasive 
or well-differentiated tumours, surgery 
alone could be curative, while larger 
tumours with advancing stage and ill-
defined margins may require other forms 
of adjunctive therapies (Cassali et al., 
2011; Sorenmo et al., 2011). Examples of 
adjunctive therapies include chemotherapy, 
hormonal therapy and radiotherapy. 
However, there is no established guidelines 
for treatment beyond surgery for CMT 
patients (Sorenmo, 2003). 
In CMT patient, the best surgical plan 
involves removing all of the affected tissue 
with wide surgical margins (Novosad, 
2003). Nodulectomy or lumpectomy may 
be performed on singular, small sized 
tumours (about 0.5 cm), while larger and 
more aggressive tumours will require 
mastectomy (either simple, in block or 
radical mastectomy depends on the size of 
the tumour itself) (Cassali et al., 2011).
Adjuvant chemotherapy is 
recommended for CMT patients with 
metastasis condition (stage IV – V 
CMT), and, CMT patients diagnosed 
with solid carcinomas, micropapillary 
carcinomas, anaplastic carcinomas and 
carcinosarcomas even when lymph node 
or lung metastasis is not evident (Cassali 
et al., 2011; Novosad, 2003). Commonly used 
chemotherapy drugs include doxorubicin, 
5-fluouroucil and cyclophosphamide, in 
which, doxorubicin is considered one of 
the most active agents for patients with 
advanced CMT staging (Sorenmo, 2003).
According to Sorenmo (2003), the 
development of most mammary gland 
carcinomas is oestrogen dependent and 
the majority of canine mammary gland 
carcinomas express oestrogen receptors 
(ER). Benign and well-differentiated 
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mammary gland tumours (stage I - III 
CMT) are often ER-positive and the dogs 
with ER-positive mammary gland tumour 
present a higher survival rate and are 
potential candidates for hormonal therapy 
whereas poorly differentiated and anaplastic 
mammary gland tumours (stage IV to V 
CMT) are usually ER-negative and will not 
respond well to hormonal therapy (Cassali et 
al., 2011; Ferreira, Bertagnolli, Cavalcanti, 
Schmitt, & Cassali, 2009; Sorenmo, 2003).
Staging of a CMT patient should be 
done regularly because it is also closely 
associated to the prognosis and survival 
expectation of the dog. Similar to other 
solid tumour, dogs with advanced staging 
of CMT have poorer prognosis. For 
instance, dogs diagnosed with stage IV 
CMT (lymph node metastasis presence) 
have a shorter survival time compared to 
dogs with stage III CMT (without lymph 
node metastasis) (Matos et al., 2012; 
Sorenmo et al., 2011). Therefore, dogs 
diagnosed with a lower stage of CMT 
will have longer survival time. Canine 
mammary gland tumour classified as 
inflammatory carcinomas are highly 
aggressive and patient’s survival time is 
typically less than one month (Clemente 
et al., 2013; Sorenmo, 2003).
Table 3
Staging system for canine mammary gland tumours
Stage Original WHO Staging System 
(Owens, 1980)
Stage Modified WHO Staging System (Rutteman & Withrow, 2001)
I T1a, b, c N0 M0 I T1 N0 M0
II
T0 N1 M0
II T2 N0 M0T1a, b, c N1 M0
T2a, b, c N1 or N1a M0
III
T3a, b, c anyN M0 III T3 N0 M0anyT anyNb M0
IV anyT anyN M1 IV anyT N1 M0
V No Stage V V anyT anyN M1
T:  primary tumour (a: not fixed; b: fixed to skin; c: fixed 
to muscle)
T0: no evidence of tumour
T1: <3cm maximum diameter (a, b, c)
T2: 3-5cm maximum diameter (a, b, c)
T3: >5cm maximum diameter (a, b, c)
T4: any T, inflammatory carcinoma
N: regional lymph node status (a: not fixed; b: fixed)
Assessed by clinical examination or histopathology
N0: no metastasis
N1: metastasis ipsilateral lymph node (a, b)
N2: metastasis bilateral lymph node (a, b)
M: distant metastasis
M0: no distant metastasis
M1: distant metastasis detected
a Excluding inflammatory carcinoma
T: primary tumour 
T1: <3cm maximum diameter 
T2: 3-5cm maximum diameter 
T3: >5cm maximum diameter 
N: regional lymph node status 




M0: no distant metastasis
M1: distant metastasis detected
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Histologic Grading of Canine 
Mammary Gland Tumours
Histologic malignant grade of tumour is 
a simple histological assessment done on 
Haematoxylin and Eosin (H&E) stained 
tissue slides that is used to determine the 
extent of differentiation of solid tumours. 
There is no specific grading system for 
CMT, however, the “Elston and Ellis grading 
method” for human breast adenocarcinoma 
has been applied on CMT and found to be 
associated with prognosis in the affected 
dogs (Karayannopoulou, Constantinidis, 
& Dessiris, 2005). The grading method 
evaluates the tubule formation in the tumour 
tissue, nuclear pleomorphism and mitosis 
per 10 high power field (Goldschmidt et 
al., 2011). The tubule formation is scored 
1, 2 or 3, depending on whether the tubule 
formation in the tissue is more than 75%, 
10-75% and less than 10% respectively. The 
nuclear pleomorphism is scored 1, 2 or 3, 
depending on whether the nuclear size is 
uniform, moderately variable shape and size 
and marked variation in size respectively. 
The mitoses criteria is scored 1, 2 or 3 if there 
are 0 to 9 mitotic figures, 10 to 19 mitotic 
figures and more than 20 mitotic figures 
per 10 high power fields respectively. If the 
total score of a tissue is 3 to 5, it is scored as 
grade 1 (low grade). If the score is 6 to 7, it 
is scored as grade 2 (intermediate grade). If 
the total score of a tissue is 8 to 9, it is scored 
grade 3 (high grade).
Therapeutic Modalities
Surgery. Surgical excision is the 
recommended therapeutic procedure for 
the treatment of CMT (Cassali et al., 2011; 
Novosad, 2003), and is also the most 
widely used form of treatment (Novosad, 
2003). In the absence of metastasis, 
surgery has the highest chance of curing 
the condition (Cassali et al., 2011). In 
addition to improving survival time and 
quality of life, by eliminating pain and 
discomfort, surgically excised tumours 
allow for more in-depth examination by 
histopathology (Cassali et al., 2011). The 
extent and type of surgery to be performed 
is determined by the characteristics of 
the tumour. The size and location of the 
lesion, extent of the disease and lymphatic 
drainage are all considered in the choice 
of surgical procedure to be performed. 
Nodulectomy or lumpectomy may be 
done on small sized tumours (about 0.5 
cm), while larger and more aggressive 
tumours require mastectomy (simple, in 
block or radical) (Cassali et al., 2011). 
While some researchers recommend 
the excision of the whole mammary 
chain to prevent recurrence, some argue 
that there is no difference in recurrence 
and survival of these patients compared 
to those that undergo local excision 
(Novosad, 2003). In small, non-invasive 
or well demarcated tumours, surgery 
alone could be curative, while larger 
tumours with ill-defined margins may 
require other forms of adjunctive therapies 
(Cassali et al., 2011). Figure 5 shows a 
dog with recurrent or regrowth of invasive 
mammary carcinoma after mastectomy, 
due to high grade of the tumour and poor 
surgical margins.
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Figure 5. A dog presented with regrowth of invasive mammary adenocarcinoma after initial mastectomy due 
to high grade of the tumour and poor surgical margins 
Chemotherapy. Although chemotherapy 
is incorporated into the treatment of 
CMT, its efficacy is not fully established 
in veterinary practice (Novosad, 2003). 
Doxorubicin is among the common 
cytotoxic drug used in the treatment of 
CMT. It has been shown to have some 
antitumour effect on CMT cell lines in-
vitro (Novosad, 2003). Doxorubicin can 
be used alone or in combination with 
cyclophosphamide (Cassali et al., 2011). 
Carboplatin and Cisplatin can also be used 
in the treatment of CMT, although there is 
still the need to establish the true efficacy 
of each of these drugs in the treatment 
of CMT (Cassali et al., 2011). Recently, 
gemcitabine has been used in the treatment 
of CMT, usually in a combination with a 
platinum-based drug such as Carboplatin 
(Cassali et al., 2011).
Anti-Inflammatory. In dogs with 
inflammatory mammary carcinoma, 
treatment with piroxicam (a non-steroidal 
anti-inflammatory drug) produce a positive 
clinical response and improved quality 
of life, with a longer mean survival time 
compared to the mean survival time of 
dogs treated  with doxorubicin (Souza , 
Toledo-piza, Amorin, Barboza, & Tobias, 
2009). The study also reported that 100% 
of the dogs treated with doxorubicin-
cyclophosphamide chemotherapy 
combination died within one month of 
treatment, but the piroxicam treated dogs 
had a mean survival time of 174 days. 
Surgery is not commonly recommended 
in dogs with inflammatory mammary 
carcinoma, but drugs that can reduce pain, 
in association with some anti-cancer drugs 
are recommended and firocoxib has been 
recently proposed as a palliative treatment 
(Cassali et al., 2011).
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Hormonal Therapy. Hormonal therapy 
is employed in human practice in patients 
with oestrogen receptor-positive (ER+) 
breast tumours (Novosad, 2003). Such 
ER+ tumour patients have a favourable 
prognosis (Martin De Las Mulas et al., 
2004) and are the targets for hormonal 
therapy in breast cancer in humans and 
mammary gland tumours in dogs (Cassali 
et al., 2011). Tamoxifen (an antiestrogenic 
agent) has been suggested in the treatment 
of spayed dogs with ER+ CMT, although 
side-effects such as pyometra, mammary 
masses/secretions and death have been 
observed in the study involving 20 healthy 
dogs (10 intact and 10 spayed). A controlled 
dose for up to 120 days is suggested with 
assessment and control of side effects 
(Tavares et al., 2010). The efficacy of 
hormonal therapy is ambiguous in CMT, 
as conflicting results of success and failure 
have been reported (Novosad, 2003).
Palliative Radiation Therapy. Radiation 
therapy is not commonly used as 
primary therapy in the management of 
CMT, except in non-resectable tumours 
(inflammatory mammary carcinoma), or 
incomplete resection of tumours and as 
palliative treatment (Novosad, 2003). The 
major disadvantage of radiotherapy is the 
development of secondary tumours and 
other abnormalities such as fat necrosis 
(Looper, 2007). Moreover, radiation has 
been used to induce mammary cancers 
experimentally in dogs (Benjamin et al., 
1999; Deeg et al., 1983). In an experimental 
study, intraoperative radiation therapy 
was done on adult dogs to determine its 
short and long term effects on tissues and 
organs, leading to the development several 
types of cancers in the dogs (Barnes et 
al., 1990). This is also a similar scenario 
where radiotherapy has been associated 
with the development of lung cancer 
and cardiomyopathies in human patients 
diagnosed with breast cancer (Jabbari et 
al., 2013; Travis et al., 2012). 
Prognostic Factors
Several prognostic factors have been 
identified for the dogs diagnosed with 
mammary tumours (Table 4). The 
prognostic factors may be associated with 
the dog itself, the tumour characteristics or 
even the various markers that the tumour 
expresses, where they have been described 
in reports as independent prognostic factors. 
Among the most important prognostic 
factors in CMT is the histopathological 
detection of regional lymph node metastasis 
(Klopfleisch et al., 2010a), that contributes 
to poor postsurgical survival (Rasotto et 
al., 2012).
Immunohistochemistry. Immunohistochemistry 
is a technique to specifically evaluate 
the distribution of protein or antigen 
in biological tissues using specific 
antibodies (Ramos-Vara, 2005). 
Immunohistochemistry is one of the popular 
techniques which is commonly used to 
describe and evaluate protein expression 
for prognosis, survival, predict response to 
therapy or even used to identify proteins/ 
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antigens suitable for development of novel 
therapeutics. Markers that have been 
evaluated using immunohistochemistry 
on CMT are Ki67, Cox-2, proliferating 
cell nuclear antigen (PCNA), oestrogen 
receptor (ER) and progesterone receptor 
(PR), CD31, vascular endothelial growth 
factor (VEGF), vascular endothelial growth 
factor receptor-2 (VEGFR-2), E-cadherin 
and β –catenin (adhesion molecules), 
human epidermal growth factor receptor 
(HER-2) (proto-oncogene), p53 (tumour 
suppressor), breast cancer susceptibility 
gene (BRCA1, BRCA2) (genetic stability 
gene) and p63 (myoepithelial cell nuclear 
marker). All  the aforementioned markers 
are significant prognosticators ( Cassali et 
al., 2011; Gama, Alves, Gartner, & Schmitt, 
2003; Klopfleisch, Lenze, Hummel, & 
Gruber, 2010b; Queiroga et al., 2011).
Table 4
Prognostic indicators of canine mammary gland tumours
Factor Influence on prognosis References
Age Shorter DFS and OS with increased age (Bonnet, Egenvall,  Hedhammar, & Olson, 
2005;  Hellmén et al., 1993; Schneider,  
Dorn, & Taylor, 1969; Simon,  Schoenrock,  
Baumgärtner, & Nolte 2006)
Breed size Small breed dogs have longer postsurgical survival (Itoh et al., 2005)
Spay Dogs spayed <2years before surgery survived longer 
that dogs spayed >2years before surgery
(Sorenmo et al., 2000)
Diet Low fat high protein diet confers longer survival time 
than high fat low protein diet
(Sorenmo et al., 2000)
Clinical signs Short duration of clinical signs have poor prognosis (Sorenmo et al., 2000)
Clinical follow up Lack of clinical follow up have poorer prognosis (Matos et al., 2012)
Tumour size >3cm have poor prognosis (Matos et al., 2012; Sorenmo et al., 2000, 2011)
Tumour growth Invasive growth confers poorer prognosis (Matos et al., 2012; Sassi, Sarli,  Brunetti, 
Morandi, & Benazzi, 2008)
Tumour grade Grade 3 have poorer prognosis (Hellmén et al., 1993; Sassi et al., 2008)
Tumour stage High stage tumours have a shorter overall survival (Hampe & Misdorp, 1974; Hellmén et al., 
1993; Sorenmo et al., 2011)
Tumour type Simple carcinoma has better prognosis, malignant 
mixed tumours, inflammatory carcinoma have poor 
prognosis, primary Sarcoma have poor prognosis, 
(Benjamin et al., 1999; Sorenmo et al., 2011, 
2000; Souza et al., 2009)
Lymph node Metastasis to regional lymph node have poor 
prognosis
(Hellmén et al., 1993; Klopfleisch et al., 2010a; 
Sorenmo et al., 2011)




Expression of oestrogen receptors and progesterone 
receptors confer better prognosis. Growth hormone 
and Insulin-like growth factor expression linked to 
poor prognosis 
(Queiroga et al., 2005; Queiroga et al., 2011; 
Sleeckx et al., 2011; Sorenmo et al., 2011)
Proliferation 
markers
Ki67 and Proliferating cell nuclear antigen expression 
linked to poor prognosis
(Queiroga et al., 2005; Klopfleisch et al., 
2011b; Zuccari et al., 2008)
Other markers 
expression
P53 mutation confers poor prognosis.
EMT (Vimentin) expression confers poor prognosis. 
HER2 over expression confers poor prognosis. 
Interleukin 8 expression confers better prognosis. 
Cyclooxygenase 2 over expression confers poor 
prognosis
(Klopsfeisch et al., 2011; Queiroga et al., 2005; 
Rungsipipat et al., 1999; Sorenmo et al., 2011; 
Uva et al, 2009; Zuccari et al., 2011)
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Carcinosarcomas showed high 
VEGFR-2 expression on 
immunohistochemistry which suggesting 
that it may be one of the activated molecular 
pathways in this aggressive tumour type 
and that VEGFR-2 inhibitors may be 
used as potential treatment to improve the 
prognosis of affected dogs. Both VEGF 
and VEGFR-2 immunoreactivities were 
independent of patients’ overall survival 
(OS) and disease-free survival (DFS) 
(Santos, Lopes, Gärtner, & Matos, 2016). In a 
similar report, 26 canine simple mammary 
adenocarcinomas were found to express 
markers associated with angiogenesis 
including VEGF and VEGFR-2 at 96% and 
100% of the tissues. Vascular endothelial 
growth factor may stimulate tumour cell 
proliferation through an autocrine loop, 
since VEGF and VEGFR-2 were expressed 
in most tumours (Al-Dissi,  Haines, 
Singh, & Kidney, 2010). VEGF is able to 
increase the microvascular permeability 
(Nakamura, Savinvov, Lu, & Brodie, 
2013) thus, tumours with higher expression 
of VEGF and receptors may also stimulate 
the neoplastic cell migration through 
lymphatic vessels.
Ki-67. This antigen is a nuclear protein 
actively expressed in cycling cells, but 
not after mitosis (Gerdes et al., 1984).  It 
has been found to be expressed in many 
tumours of the dog and man (Queiroga, 
Raposo, Carvalho, Prada, & Pires, 2011). 
A poor prognosis has been linked to 
immunohistochemical expression of Ki-
67 in dogs with CMT (Peña, Nieto, Pérez-
Alenza, Cuesta, & Castaño, 1998). Ki-67 
expression has been associated with a short 
disease free and overall survival time as 
well as correlates with advanced histologic 
tumour grade (Morris et al., 2009; Sarli, 
Preziosi, Benazzi, Castellani, & Marcato, 
2002).
Proliferating Cell Nuclear Antigen
Knowing the proliferation status of any 
tumour is an important basis for the 
determination of the malignancy of the 
tumour and prognosis (Funakoshi et al., 2000; 
Torres et al., 2005). Proliferating cell nuclear 
antigen (PCNA) is a protein synthesised by 
cells in the S-phase of the cell cycle and it 
is seen accumulated in the nucleolus of the 
cells in the late G1 and early S-phases of the 
cell cycle (Mathews, Bernstein, Franza, & 
Garrels, 1984; van Dierendonck, Wijsman, 
Keijzer, van de Velde, & Cornelisse, 
1991). Immunohistochemical detection of 
PCNA expressed in tumour cells has been 
critical in the evaluation of the proliferative 
activity of the tumours (Sarli et al., 2002). 
In CMT, PCNA expression has been found 
to correlate with aggression of tumours 
and has been described as an indicator of 
malignancy (Funakoshi et al., 2000; Peña et 
al., 1998; Queiroga et al., 2011; Torres et al., 
2005). 
In CMT, PCNA expression positively 
correlates with a shorter disease-free 
interval (Löhr, Teifke, Failing, & Weiss, 
1997). Co-expression of PCNA and other 
prognostic markers have been analysed 
and PCNA expression is co-related with 
Ki-67 in dysplasias and benign mammary 
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tumours in the dog (Löhr et al., 1997; 
Nowak, Madej, Dziegiel, & Kanzawa, 
2006; Peña et al., 1998). Expression of 
PCNA was found to inversely correlate 
with oestrogen receptor alpha (ERα) 
(Perez-Alenza et al., 2000). This finding 
suggests that as the tumour advances, 
hormonal dependency is lost and neoplastic 
cells increase in cell proliferation where 
malignancy is acquired. 
Vimentin. Epithelial-mesenchymal transition 
(EMT) in tumours allows epithelial cells to 
transform into mesenchymal cells capable 
of migration and tissue invasion, which 
are the first steps in the establishment of 
metastasis (Wu et al., 2006). This transition 
is characterised by the overexpression 
of certain intermediate filaments such 
as Vimentin (Genelhu, Cardoso, Gobbi, 
& Cassali, 2007; Mendez, Kojima, & 
Goldman, 2010; Yoshida et al., 2013). 
Vimentin has been shown to be expressed 
in myoepithelial and mesenchymal cells, as 
well as overexpressed in CMT. Vimentin 
expression has also been used to identify 
CMT with luminal epithelial lineage 
(Griffey et al., 1993; Rabanal & Else, 1994; 
Toniti et al., 2009). However, the status of 
Vimentin as a prognosticator in CMT is yet 
to be ascertained as conflicting findings 
have been reported (Vos et al., 1993).
Oestrogen Receptor (ER). Oestrogen 
plays a major role in mammary gland 
development and oestrous cycle through 
the activation of oestrogen receptors 
(Chang et al., 2009; Martin De Las Mulas 
et al., 2004; Rehm, Stanislaus, & Williams, 
2007). Two forms of oestrogen receptors 
ERα and ERβ have been reported in 
the literature (Chang et al., 2009). Favourable 
prognosis has been linked to oestrogen 
receptor expression in malignant mammary 
tumours (Martin De Las Mulas et al., 2004). 
Oestrogen receptors are reported to be 
expressed in more benign than malignant 
CMT (Chang et al., 2009). Tumours that 
are less than 5 cm in diameter and without 
nodal or distant metastasis are associated 
with oestrogen receptor expression (Chang 
et al., 2009). 
Progesterone Receptor (PR). 
Progesterone plays a significant role in 
oestrous cycle and pregnancy through the 
activation of progesterone receptors (Rehm 
et al., 2007). In canine mammary tumours, 
PR expressing tumours have been found to 
be more benign than malignant, less than 
5cm in diameter have no lymph node or 
distant metastasis and the dogs survive 
longer than those with tumours expressing 
only Oestrogen receptors (Chang et al., 
2009). Progesterone receptor has been 
targeted with success for therapy in PR 
positive canine mammary carcinoma cells 
(Guil-Luna et al., 2011). Absence of any 
correlation between PR expression and 
tumour subtype has also been reported in 
CMT (Toniti et al., 2009).    
Recent Advancements in Therapeutics 
for CMT
There has been limited advancement in the 
improved or advanced therapies for dogs 
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with mammary tumour for the past decade. 
Several studies are underway investigating 
novel strategies, however most of the 
evidence is preliminary in vitro and in 
vivo mice models (Table 5). Increasing the 
awareness on spaying dogs at early age 
may collectively help reduce the incidence 
of CMT.  
Table 5 







research conclusion References 
Gold nanorods plasmonic 
photothermal therapy 
(AuNRs-PPTT)
5 female dogs 
(spontaneous 
clinical cases)
Causes heat-induced necrosis and 
apoptosis of the cancer cells leading 
to complete regression of tumours
(Ali,  Ibrahim, Ali, 
Selim, & El-Sayed, 
2016)




DNA methyl transferase (DNMT) 
inhibition in over expressing cancer 
cells
(Harman,  Curtis, 
Argyle,  Coonrod, 




CMT cell lines and 
mice models
Reovirus causes caspase-dependent 
apoptosis in CMT cells and 
prevents development of tumours in 
mice. Enhances cytotoxic effects of 
chemotherapeutic drugs at half the 
IC50 in combination with reovirus
(Igase et al., 2016)
Metformin
CMT cell lines and 
mice models
Causes AMPK-independent cell 
cycle arrest in vitro and suppresses 
tumour development in mice 
models
(Saeki et al., 
2015a)
Mice models of 
lung metastatic 
CMT cell lines
Blocks EMT via N-cadherin, 
leading to reduction in metastases
(Leonel et al., 
2017)
Mitochondrial respiratory 
chain complex inhibitors 
(antimycin, oligomycin 
and rotenone) 
CMT cell lines 
(metastatic and non-
metastatic clones)
Mitochondrial ATP depletion in 
cancer cells by the agents result in 
cell growth 
(Saeki et al., 
2015b)
Melphalan and BCH 
(2-amino-2-norbornane-
carboxylic acids) 
CMT cell lines L-type amino acid transporter 1 
(LAT1) inhibition
(Fukumoto et al., 
2013)
Canine Mammary Gland Tumours, 
Animal Model for Human Breast 
Cancer 
Mammary tumours are the most common 
naturally developed neoplasia in female 
dogs and women (Yoshikawa et al., 2012). 
For the past decades, CMT has been 
suggested as a large animal spontaneous 
model for human breast cancer (Nerurkar, 
Chitale, Jalnapurkar, Naik, & Lalitha, 1989; 
Queiroga et al., 2011). This suggestion 
is supported by the epidemiological and 
Pertanika J. Trop. Agric. Sci. 41 (2): 541 – 574 (2018)
Review on Mammary Gland Tumours in the Dog
565
histopathological similarities that have 
been observed between the two (Queiroga 
et al., 2011) and the failure of mouse models 
(transgenic and xenografts) to mimic the 
tumour heterogeneity, dependence on 
steroids and tumour microenvironment, 
which are the essential features of human 
breast cancer (Uva et al., 2009). 
The prevalence of mammary tumours 
is higher in dogs compared to women, 
which gives CMT an edge over human 
breast cancer in terms of availability for 
research and clinical trials (Queiroga et al., 
2011; Nerurkar et al., 1989; Yoshikawa et 
al., 2012). Age as risk factor of mammary 
neoplasia has a somewhat similar influence 
in both human breast cancer and canine 
mammary gland tumours. It is reported 
that the age for onset of mammary tumours 
in dogs is after six years and peak age of 
occurrence is eight to 11 years, while 40 
years of age is the reported onset age in 
human breast cancer and 50 to 58 years 
is the peak age of occurrence (Queiroga 
et al., 2011). The use of postmenopausal 
hormone replacement therapies have been 
linked to an increased risk of breast cancer 
in women (Amadou, Fabre, Torres-Mejía, 
& Ortega-Olvera, 2013) while the influence 
of ovarian hormones in CMT occurrence as 
demonstrated by early ovariectomy or lack 
of it has also been reported (Queiroga et 
al., 2011; Sorenmo et al., 2011). It has been 
reported that certain breeds are at a higher 
risk of developing CMT (Itoh et al., 2005), 
so in human breast cancer too, some races 
are reported to be more at risk compared 
to others (Pillai, Tay, Nair, & Leong, 
2012; Sullivan et al., 2013). Other factors 
such as diet and obesity as risk factors for 
developing mammary tumours are also 
reported to have similar associations in 
both dogs and humans (Sonnenschein et 
al., 1991; Amadou et al., 2013). 
The clinical presentation of mammary 
tumours is similar in dogs and humans, 
with patients presenting symptoms such 
as palpable masses of various sizes in the 
breast tissue or mammary gland chain, skin 
ulcerations, chest wall infiltration, enlarged 
lymph nodes, nipple retraction more 
notable in human, pain, and in some cases, 
pus or haemorrhage (Chang, Liao, Wong, 
Lai, & Liu, 2007; Grandi, Colodel, Rocha, 
& Sequeira, 2011; Nandeesh,  Anitha, 
& Shravan Rajpurohit, 2013; Yoneyama 
& Nakamura, 2013). Large percentage 
of the tumours are diagnosed malignant 
and the most common site of metastasis 
is the regional lymph nodes, which 
significantly influence prognosis (Queiroga 
et al., 2011).
The methods of treatment in dogs with 
mammary gland tumours are very similar to 
the approach used in human breast cancer. 
Depending on the severity and stage of the 
disease, surgical approach is considered 
the most effective treatment, either alone 
or in combination with chemotherapy or 
hormonal therapy (Cassali et al., 2011; 
Yoneyama & Nakamura, 2013). Hormonal 
therapy is not commonly employed 
in CMT treatment due to toxicity of 
tamoxifen in dogs (Tavares et al., 2010). 
Chemotherapeutic agents commonly used 
in both species include Doxorubicin, 
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cyclophosphamide, piroxicam, and 
firocoxib, to mention a few (Cassali et al., 
2011; Nandeesh et al., 2013; Novosad, 
2003). Triple negative breast cancer (ER, 
PR- and HER2-) is the most difficult cancer 
phenotype to treat, due to its lack of steroid 
hormone dependency that could be targeted 
with Tamoxifen (Kabos, et al. 2012), and has 
also been described in the canine species, 
with similar characteristics (Kim, Lim, 
Im, Kim, & Sur, 2013). Factors affecting 
postsurgical survival in patients with breast 
cancer are similar with those predicting 
survival in dogs with mammary gland 
tumours (Philibert et al., 2003). Factors 
such as histologic tumour grade, tumour 
stage, presence of lymph node or distant 
metastasis, skin ulceration, increased age at 
diagnosis, oestrogen receptor, HER2, and 
BRCA expressions described to influence 
post-mastectomy survival in breast cancer 
patients have also been shown to influence 
postsurgical survival in dogs with mammary 
gland tumours (Perez-Alenza et al., 2000; 
Philibert et al., 2003; Chang et al., 2007). 
Histopathological findings and lesions 
of CMTs and human breast cancers have 
been demonstrated to be very similar, with 
very few histological subtypes described in 
human breast cancer and yet to be described 
in CMT (Goldschmidt et al., 2011). Staging 
and histopathology grading systems used in 
human breast cancers have been effectively 
applied in CMT with minimal or no 
modifications (Goldschmidt et al., 2011; 
Philibert et al., 2003). Several breast cancer 
susceptibility genes such as BRCA, HER2 
and molecular markers are described as 
risk and prognostic factors in human breast 
cancer. These genes and markers have been 
found with similar alterations, expression 
patterns and prognostic values in CMT 
(Klopfleisch, Schütze, & Gruber, 2010c; 
Queiroga et al., 2011; Rivera & Von Euler, 
2011; Uva et al., 2009). 
Current and future areas of research 
in both canine and human mammary 
gland tumours are all geared towards the 
discovery of novel molecular markers 
and therapeutic targets that will facilitate 
diagnosis, predict prognosis and possibly 
therapeutic targets (Queiroga et al., 2011).
CONCLUSION 
Spontaneous canine mammary gland 
tumours have a significant and unique role 
in understanding cancer biology as well 
as in the development of new therapeutic 
agents for the effective treatment of the 
disease in humans and in dogs. 
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